Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegylated recombinant human endostatin - Shandong Simcere Medgenn

Next Previous
Drug Profile

Pegylated recombinant human endostatin - Shandong Simcere Medgenn

Alternative Names: Endu-PEG; PEG-ENDO; PEG-Endostar injection; Pegylated Endostar injection; SIM-0710

Latest Information Update: 28 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shandong Simcere Medgenn Bio-Pharmaceutical
  • Class Angiostatic proteins; Antineoplastics; Immunotherapies; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 May 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)
  • 28 May 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)
  • 02 Apr 2020 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT04413227)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top